Tests pasritamig with docetaxel against docetaxel alone in advanced prostate cancer
Tests pasritamig plus docetaxel in men with spreading prostate cancer.
Key facts
- Who runs it
- Janssen Research & Development, LLC
- Where
- Allentown, Atlanta, Aurora, Austin, Bala-Cynwyd, Baltimore, Bethesda, Boston, Camden, Canton, Chandler, Cincinnati, Cleveland, Dallas, Denver, Durham, East Brunswick, Edgewood, Edwards, Fairfax, Fountain Valley, Grand Junction, Hershey, Houston, Jackson, Knoxville, La Jolla, Lakewood, Lincoln, Lisle, Little Rock, Los Alamitos, Los Angeles, Louisville, Metairie, Mineola, Myrtle Beach, New Brunswick, New York, Orlando, Pembroke Pines, Pittsburgh, Riverside, Saint Louis Park, Saint Paul, San Diego, Santa Monica, Sarasota, Seattle, Sioux Falls, Springdale, Springfield, St Louis, Sterling Heights, Sugar Land, The Bronx, The Woodlands, Towson, Watertown, and Wichita, United StatesSee the 65 sitesAlso in 16 other countries, 100 sites
- Trial code
- Registry title
- A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 800 people, planned
- Started
- 19 Dec 2025
- Expected to end
- 7 Jun 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Pasritamig
- Docetaxel
- Prednisone/Prednisolone
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with prostate cancer that has spread and keeps growing despite hormone-lowering treatment. It tests pasritamig with docetaxel against docetaxel alone.
- Age
- 18 years or older
- Sex
- All sexes listed by the registry; the cancer studied is prostate cancer.
- Disease stage
- Prostate adenocarcinoma confirmed under the microscope, spread to other parts of the body (metastatic) on CT or MRI and a bone scan. Ongoing hormone-lowering treatment (or earlier surgery to remove both testicles) with testosterone at or below 50 ng/dL. Daily activity level (ECOG) of 0 to 1.
- Earlier treatment
- The cancer must have progressed on at least 1 but no more than 2 different androgen receptor pathway inhibitors, which must be stopped before joining. No earlier chemotherapy for prostate cancer and no earlier treatment aimed at KLK-2.
- Biomarker or test result
- Participants with known BRCA 1/2 gene changes must have already had a PARP inhibitor, unless it was not available or not safe for them.
Main reasons for not taking part
- Known cancer spread to the brain or the membranes around it
- Known BRCA 1/2 change without earlier PARP inhibitor treatment, unless not available or not safe
- Another cancer, past or current, besides the prostate cancer
- Earlier chemotherapy for prostate cancer in any setting
- Earlier treatment directed at human kallikrein 2 (KLK-2)
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Have histologically confirmed adenocarcinoma of the prostate
- Have disease that is metastatic at the time of screening by computed tomography (CT) or magnetic resonance imaging (MRI) and 99m\^Tc bone scan as determined by the investigator
- Participants must receive ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone (GnRH) analog throughout the treatment or have had prior bilateral orchiectomy, and have serum testosterone less than or equal to (<=) 50 nanogram per deciliter (ng/dL) (<= 1.73 nanomoles per Liter [nmol/L]) at screening
- Have progressed by PSA or CT/MRI or 99m\^Tc bone scan on at least 1 novel androgen receptor pathway inhibition (ARPI) but no more than 2 different ARPI for any stage of disease. Must have discontinued ARPI before randomization into the study
- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1
Who cannot take part
- Participants with known breast cancer gene 1/2 (BRCA 1/2) mutations (germline or somatic) who have not received treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor, unless not available or contraindicated
- Prior or concurrent second malignancy (other than the disease under study)
- Received cytotoxic chemotherapy for prostate cancer in any setting
- Received prior treatment with human kallikrein 2 (KLK-2) directed therapies
- Known history of either brain or leptomeningeal prostate cancer metastases
Where in United States
Also in 16 other countries, 100 sites
- LeHigh Valley HospitalAllentown, United StatesTaking people
- Winship Cancer Institute, Emory UniversityAtlanta, United StatesTaking people
- Rocky Mountain Cancer CentersAurora, United StatesTaking people
- Texas OncologyAustin, United StatesTaking people
- MidLantic UrologyBala-Cynwyd, United StatesTaking people
- Johns Hopkins HospitalBaltimore, United StatesTaking people
- Johns Hopkins Medical InstitutionsBaltimore, United StatesTaking people
- University of MarylandBaltimore, United StatesTaking people
- Center for Cancer and Blood DisordersBethesda, United StatesTaking people
- Massachusetts GeneralBoston, United StatesTaking people
- Cooper Health System MD Anderson Cancer Center at CooperCamden, United StatesTaking people
- Gabrail Cancer CenterCanton, United StatesTaking people
- Arizona Clinical TrialsChandler, United StatesTaking people
- University of CincinnatiCincinnati, United StatesTaking people
- MetroHealth Medical CenterCleveland, United StatesTaking people
- UT Southwestern Medical CenterDallas, United StatesTaking people
- AdventHealth Porter Oncology ResearchDenver, United StatesTaking people
- Duke University Medical CenterDurham, United StatesTaking people
- Astera Cancer CareEast Brunswick, United StatesTaking people
- St. Elizabeth HealthcareEdgewood, United StatesTaking people
- Vail Health Shaw Cancer CenterEdwards, United StatesTaking people
- Virginia Cancer SpecialistsFairfax, United StatesTaking people
- MemorialCare - Orange Coast Medical CenterFountain Valley, United StatesTaking people
- Grand Valley OncologyGrand Junction, United StatesTaking people
- Penn State Milton S. Hershey Medical CenterHershey, United StatesTaking people
- Houston Metro UrologyHouston, United StatesTaking people
- University of Mississippi Medical CenterJackson, United StatesTaking people
- Tennessee Cancer SpecialistsKnoxville, United StatesTaking people
- University of California San DiegoLa Jolla, United StatesTaking people
- Colorado Clinical ResearchLakewood, United StatesTaking people
- NHO Revive Research Institute, LLCLincoln, United StatesTaking people
- Duly Health and CareLisle, United StatesTaking people
- Arkansas UrologyLittle Rock, United StatesTaking people
- Cancer and Blood Specialty ClinicLos Alamitos, United StatesTaking people
- Ronald Reagan UCLA Medical CenterLos Angeles, United StatesTaking people
- USC / Norris Comprehensive Cancer CenterLos Angeles, United StatesTaking people
- Valkyrie Clinical TrialsLos Angeles, United StatesTaking people
- Norton Cancer InstituteLouisville, United StatesTaking people
- East Jefferson General HospitalMetairie, United StatesTaking people
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long IslandMineola, United StatesTaking people
- Carolina Urologic Research CenterMyrtle Beach, United StatesTaking people
- Rutgers Cancer Institute of New JerseyNew Brunswick, United StatesTaking people
- NYU Langone Health Laura and Isaac Perlmutter Cancer CenterNew York, United StatesTaking people
- AdventHealth OrlandoOrlando, United StatesTaking people
- Memorial Cancer InstitutePembroke Pines, United StatesTaking people
- University of Pittsburgh Medical Center (UPMC) - Hillman Cancer CenterPittsburgh, United StatesTaking people
- Kaiser Permanente Southern CaliforniaRiverside, United StatesTaking people
- HealthPartners Frauenshuh Cancer Center CRC WestSaint Louis Park, United StatesTaking people
- HealthPartners Cancer Center at Regions Hospital CRC EastSaint Paul, United StatesTaking people
- Sharp Center for ResearchSan Diego, United StatesTaking people
- Providence Saint John's Health CenterSanta Monica, United StatesTaking people
- Florida Cancer SpecialistsSarasota, United StatesTaking people
- Fred Hutch Cancer Center Sloan Clinic 2Seattle, United StatesTaking people
- Fred Hutchinson Cancer Research CenterSeattle, United StatesTaking people
- Avera Medical GroupSioux Falls, United StatesTaking people
- Highlands Oncology GroupSpringdale, United StatesTaking people
- Oregon Urology InstituteSpringfield, United StatesTaking people
- Washington UniversitySt Louis, United StatesTaking people
- Profound Research LLC at Cancer and Leukemia CenterSterling Heights, United StatesTaking people
- Texas Oncology 1Sugar Land, United StatesTaking people
- Montefiore Medical CenterThe Bronx, United StatesTaking people
- Renovatio ClinicalThe Woodlands, United StatesTaking people
- Chesapeake Urology Research AssociatesTowson, United StatesTaking people
- Prairie Lakes Health Care SystemWatertown, United StatesTaking people
- Cancer Center of Kansas, Heritage Plaza Medical BuildingWichita, United StatesTaking people
About the trial
What the trial wants to find out
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).
The 2 groups in the trial
- Pasritamig+DocetaxelTreatment being tested
Participants will receive pasritamig along with docetaxel until the end of treatment (EOT) visit or until radiographic disease progression is confirmed by blinded independent central review (BICR), or any other protocol defined criteria are met.
Treatment: Pasritamig and Docetaxel
- DocetaxelExisting treatment, for comparison
Participants will receive docetaxel along with prednisone/prednisolone as background medication.
Treatment: Docetaxel and Prednisone/Prednisolone
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-engaging Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer
- Plain-language title
- Tests pasritamig with docetaxel against docetaxel alone in advanced prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 3 November 2026